SuperHERO: A Phase II Trial Evaluating Radiotherapy Omission for Low-risk HER2-positive Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07895511

Title field or adapter rule

{'original_value': 'SuperHERO: A Phase II Trial Evaluating Radiotherapy Omission for Low-risk HER2-positive Breast Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:27.854372+00:00

Published At

2026-10-29T00:00:00+00:00

Record Updated At

2026-10-29

Source Retrieved At

2026-10-31T22:18:24.976182+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["HER2-positive Breast Cancer", "Breast Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-29", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07895511"

protocolSection.identificationModule.officialTitle

"SuperHERO: A Phase II Trial Evaluating Radiotherapy Omission for Low-risk HER2-positive Breast Cancer"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["NA"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• HER2-positive Breast Cancer (protocolSection.conditionsModule.conditions)
• Breast Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['HER2-positive Breast Cancer'], 'description': 'Participants will continue to receive standard HER2-targeted therapy as part of their usual care', 'name': 'HER2-targeted therapy', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['HER2-positive Breast Cancer'], 'description': "If participants' cancer is hormone receptor-positive, participants may also receive endocrine therapy as part of their usual care.", 'name': 'Tamoxifen', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['HER2-positive Breast Cancer'], 'description': 'Participants will not receive radiation therapy to their breast after their lumpectomy.', 'name': 'No Radiation Therapy', 'type': 'RADIATION'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• HER2-targeted therapy (protocolSection.armsInterventionsModule.interventions[].name)
• Tamoxifen (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.